An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer

Breast

Volumn 22, Issue 5, 2013, Pages 974-979

  Pérez Fidalgo, Jose A ^a   Eroles, Pilar ^b   Ferrer, Jaime ^c   Bosch, Ana ^a   Burgués, Octavio ^c   Martínez, Francisco ^b   Bermejo, Begoña ^a   Lluch, Ana ^a   González Angulo, Ana M ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Instituto Universitario IVI INCLIVA   (Spain)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Estrogen receptor; HER2; Metastatic breast cancer; Progesterone receptor; Technical bias

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ASSESSMENT; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; TUMOR BIOPSY;

ESTROGEN RECEPTOR; HER2; METASTATIC BREAST CANCER; PROGESTERONE RECEPTOR; TECHNICAL BIAS;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84884145043     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.05.014     Document Type: Article

References (37)

1. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23(19):4265-4274.
2. McArthur H.L., Morris P.G. Aromatase inhibitor strategies in metastatic breast cancer. Int J Womens Health 2010, 1:67-72.
3. Amir E., Miller N., Geddie W., Freedman O., Kassam F., Simmons C., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012, 30(6):587-592.
4. Amir E., Clemons M., Freedman O.C., Miller N., Coleman R.E., Purdie C., et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol 2010, 28(15s). Asco meeting abstract 1007.
5. Broom R.J., Tang P.A., Simmons C., Bordeleau L., Mulligan A.M., O'Malley F.P., et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res. 2009, 29(5):1557-1562.
6. Holdaway I.M., Bowditch J.V. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983, 52(3):479-485.
7. Hull D.F., Clark G.M., Osborne C.K., Chamness G.C., Knight W.A., McGuire W.L. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983, 43(1):413-416.
8. Karlsson E., Lindstrom L.S., Wilking U., Skoog, Johansson U., Bergh J., et al. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010, 28(15s). Asco meeting abstract 1009.
9. Li B.D., Byskosh A., Molteni A., Duda R.B. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994, 57(2):71-77.
10. Lipton A., Leitzel K., Ali S.M.D., Demers L., Harvey H.A., Chaudri-Ross H.A., et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005, 104(2):257-263.
11. Lower E.E., Glass E.L., Bradley D.A., Blau R., Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005, 90(1):65-70.
12. Mobbs B.G., Fish E.B., Pritchard K.I., Oldfield G., Hanna W.H. Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol 1987, 23(6):819-826.
13. Raemaekers J.M., Beex L.V., Koenders A.J., Pieters G.F., Smals A.G., Benraad T.J., et al. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 1984, 20(8):1011-1018.
14. Regitnig P., Schippinger W., Lindbauer M., Samonigg H., Lax S.F. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004, 203(4):918-926.
15. Simmons C., Miller N., Geddie W., Gianfelice D., Oldfield M., Dranitsaris G., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20(9):1499-1504.
16. Liedtke C., Broglio K., Moulder S., Hsu L., Kau S.W., Symmans W.F., et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20(12):1953-1958.
17. Chiang A.C., Massague J. Molecular basis of metastasis. N Engl J Med 2008, 359(26):2814-2823.
18. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464(7291):999-1005.
19. Lopez-Guerrero J.A., Llombart-Cussac A., Noguera R., Navarro S., Pellin A., Almenar S., et al. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int J Cancer 2006, 118(7):1743-1749.
20. McCarty K.S., Miller L.S., Cox E.B., Konrath J., McCarty K.S. Estrogen receptoranalyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 109(8):716-721.
21. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17(5):1474-1481.
22. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28(16):2784-2795.
23. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
24. Campbell F.C., Blamey R.W., Elston C.W., Morris A.H., Nicholson R.I., Griffiths K., et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981, 2(8259):1317-1319.
25. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93(5):552-556.
26. Arslan C., Sari E., Aksoy S., Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 2011, 15(1):21-30.
27. Gancberg D., Di Leo A., Cardoso F., Rouas G., Pedrocchi M., Paesmans M., et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13(7):1036-1043.
28. Gong Y., Booser D.J., Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103(9):1763-1769.
29. Guarneri V., Giovannelli S., Ficarra G., Bettelli S., Maiorana A., Piacentini F., et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13(8):838-844.
30. Locatelli M.A., Curigliano G., Fumagalli L., Bagnardi V., Aurilio G., Della Vigna P., et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. J Clin Oncol 2010, 28. Asco meeting abstract CRA1008.
31. Lower E.E., Glass E., Blau R., Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009, 113(2):301-306.
32. Santinelli A., Pisa E., Stramazzotti D., Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008, 122(5):999-1004.
33. Sari E., Guler G., Hayran M., Gullu I., Altundag K., Ozisik Y. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011, 28(1):57-63.
34. Tapia C., Savic S., Wagner U., Schönegg R., Novotny H., Grilli B., et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 2007, 9(3):R31.
35. Vincent-Salomon A., Jouve M., Genin P., Fréneaux P., Sigal-Zafrani B., Caly M., et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002, 94(8):2169-2173.
36. Hoefnagel L.D., van de Vijver M.J., van Slooten H.J., Wesseling P., Wesseling J., Westenend P.J., et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010, 12(5):R75.
37. Teixeira M.R., Pandis N., Bardi G., Andersen J.A., Mitelman F., Heim S. Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra-and extra-tumorous samples from 3 patients. Int J Cancer 1995, 63(1):63-68.